Related Experiment Videos
Transurethral resection of 1250 bladder tumours
1Department of Urology, Municipal Péterfy Sándor Street Hospital, Budapest, Hungary.
International Urology and Nephrology
|January 1, 1992
Summary
Transurethral resection (TUR) is effective for early-stage bladder tumors, with recurrence rates increasing with tumor stage. This procedure is best suited for Ta, T1, and select T2 bladder cancers.
Area of Science:
- Urology
- Oncology
Background:
- Transurethral resection (TUR) is a common procedure for bladder tumors.
- Assessing the efficacy and safety of TUR is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the complication and mortality rates associated with TUR for bladder tumors.
- To determine the recurrence rates and survival outcomes following TUR.
- To identify the optimal indications for curative TUR.
Main Methods:
- A retrospective analysis of 1250 bladder tumor cases undergoing TUR (curative, palliative, or biopsy).
- Data collection on complication rates, mortality, recurrence, and survival.
- Correlation of outcomes with tumor stage and grade.
Main Results:
- Overall complication rate was 9.9% and mortality rate was 0.8%.
- 1-year recurrence rate was 23.8%, 3-year rate was 36.6%, increasing with stage.
- 5-year survival rate was 66.5%; 9% died from tumor generalization within 5 years.
Conclusions:
- TUR is a viable curative option for Ta and T1 bladder tumors.
- TUR may be suitable for select T2 G1-G2 tumors.
- Outcomes are strongly influenced by tumor stage, highlighting the need for tailored treatment approaches.